Involvement of Members of the Cadherin Superfamily in Cancer

被引:548
作者
Berx, Geert [1 ,2 ]
van Roy, Frans [1 ,3 ]
机构
[1] Univ Ghent, Dept Biomed Mol Biol, B-9000 Ghent, Belgium
[2] VIB, Mol & Cellular Oncol Unit, Dept Mol Biomed Res, Ghent, Belgium
[3] VIB, Mol Cell Biol Unit, Dept Mol Biomed Res, Ghent, Belgium
关键词
EPITHELIAL-MESENCHYMAL TRANSITION; DIFFUSE GASTRIC-CANCER; HUMAN BREAST-CANCER; CELL-CELL-ADHESION; CANDIDATE TUMOR-SUPPRESSOR; ANCHORED T-CADHERIN; HUMAN HEPATOCELLULAR-CARCINOMA; HUMAN-MELANOMA CELLS; MOLECULE E-CADHERIN; PROSTATE-CANCER;
D O I
10.1101/cshperspect.a003129
中图分类号
Q2 [细胞生物学];
学科分类号
071013 [干细胞生物学];
摘要
We review the role of cadherins and cadherin-related proteins in human cancer. Cellular and animal models for human cancer are also dealt with whenever appropriate. E-cadherin is the prototype of the large cadherin superfamily and is renowned for its potent malignancy suppressing activity. Different mechanisms for inactivating E-cadherin/CDH1 have been identified in human cancers: inherited and somatic mutations, aberrant protein processing, increased promoter methylation, and induction of transcriptional repressors such as Snail and ZEB family members. The latter induce epithelial mesenchymal transition, which is also associated with induction of "mesenchymal" cadherins, a hallmark of tumor progression. VE-cadherin/CDH5 plays a role in tumor-associated angiogenesis. The atypical T-cadherin/CDH13 is often silenced in cancer cells but up-regulated in tumor vasculature. The review also covers the status of protocadherins and several other cadherin-related molecules in human cancer. Perspectives for emerging cadherin-related anticancer therapies are given.
引用
收藏
页数:27
相关论文
共 218 条
[1]
An adiponectin receptor, T-cadherin, was selectively expressed in intratumoral capillary endothelial cells in hepatocellular carcinoma: possible cross talk between T-cadherin and FGF-2 pathways [J].
Adachi, Y ;
Takeuchi, T ;
Sonobe, H ;
Ohtsuki, Y .
VIRCHOWS ARCHIV, 2006, 448 (03) :311-318
[2]
TGF-β antagonists:: Why suppress a tumor suppressor? [J].
Akhurst, RJ .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (12) :1533-1536
[3]
Prospective identification of tumorigenic breast cancer cells [J].
Al-Hajj, M ;
Wicha, MS ;
Benito-Hernandez, A ;
Morrison, SJ ;
Clarke, MF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988
[4]
Alpaugh ML, 1999, CANCER RES, V59, P5079
[5]
Molecular modeling of the extracellular domain of the RET receptor tyrosine kinase reveals multiple cadherin-like domains and a calcium-binding site [J].
Anders, J ;
Kjær, S ;
Ibáñez, CF .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (38) :35808-35817
[6]
Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment [J].
Augustine, Christina K. ;
Yoshimoto, Yasunori ;
Gupta, Mukur ;
Zipfel, Patricia A. ;
Selim, M. Angelica ;
Febbo, Phillip ;
Pendergast, Ann Marie ;
Peters, William P. ;
Tyler, Douglas S. .
CANCER RESEARCH, 2008, 68 (10) :3777-3784
[7]
EXON SKIPPING IN THE E-CADHERIN GENE TRANSCRIPT IN METASTATIC HUMAN GASTRIC CARCINOMAS [J].
BECKER, KF ;
ATKINSON, MJ ;
REICH, U ;
HUANG, HH ;
NEKARDA, H ;
SIEWERT, JR ;
HOFLER, H .
HUMAN MOLECULAR GENETICS, 1993, 2 (06) :803-804
[8]
BECKER KF, 1994, CANCER RES, V54, P3845
[9]
Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO
[10]
2-D